A New Framework for Measuring Immune Aging in Clinical Trials

Aging profoundly reshapes the immune system, degrading its ability to defend against pathogens, repair tissue damage, and maintain organ homeostasis. Because immune dysfunction touches every organ system, researchers have long suspected it acts as a central driver of biological aging — not merely a consequence. This makes immune aging an unusually attractive target both as a biomarker and a therapeutic lever in geroscience-guided clinical trials.

Despite that potential, no consensus has existed on how to actually measure immune aging in a clinical trial setting. Different research groups use different assays, different cell populations, and different composite scores, making cross-trial comparison nearly impossible and slowing the translation of promising interventions into practice.

This review, published in Nature Medicine and co-authored by a large international consortium, addresses that gap directly. The authors establish a translational framework built around five explicit evaluation criteria for immune aging biomarkers — covering properties such as reproducibility, clinical predictive value, and sensitivity to intervention. They systematically apply these criteria to a broad landscape of candidate biomarkers.

Multidimensional metrics that capture several aspects of immune function simultaneously, inflammaging scores reflecting chronic low-grade inflammation, and functional assays measuring real immune responses performed best against the criteria. The framework was also developed in the context of the XPRIZE Healthspan competition, a major international effort to accelerate human healthspan extension, giving it practical grounding in real trial design.

The authors also identify promising emerging measures — likely including systems immunology approaches and novel epigenetic or proteomic readouts — alongside critical gaps that still need to be filled before truly reliable, predictive biomarkers of immune competence can be deployed broadly. The result is a coherent roadmap intended to standardize how future trials measure immune fitness and resilience, ultimately accelerating the path from discovery to clinical benefit.